*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
Apple briefly got some of its shine back, after it delivered a package of capital programs that shareholders have been clamoring for.
Discussing business in Charlotte, the fiscal cliff and onshoring, with David Roberts, Carlisle Companies CEO.